
Ken-Ichiro Seino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9154950/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of immunosuppression protocols for MHC-matched allogeneic iPS cell-based transplantation using a mouse skin transplantation model. Inflammation and Regeneration, 2022, 42, 4.	3.7	5
2	Establishment of Human Leukocyte Antigen-Mismatched Immune Responses after Transplantation of Human Liver Bud in Humanized Mouse Models. Cells, 2021, 10, 476.	4.1	8
3	An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistance. STAR Protocols, 2021, 2, 100460.	1.2	5
4	Macrophage-like iPS-derived Suppressor Cells Reduce Th1-mediated Immune Response to a Retinal Antigen. Current Eye Research, 2021, , 1-9.	1.5	0
5	IL-34, the rationale for its expression in physiological and pathological conditions. Seminars in Immunology, 2021, 54, 101517.	5.6	12
6	Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression. International Immunology, 2020, 32, 175-186.	4.0	17
7	Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells. Inflammation and Regeneration, 2020, 40, 25.	3.7	4
8	Immune reaction and regulation in transplantation based on pluripotent stem cell technology. Inflammation and Regeneration, 2020, 40, 12.	3.7	20
9	Induction of macrophage-like immunosuppressive cells from common marmoset ES cells by stepwise differentiation with DZNep. Scientific Reports, 2020, 10, 12625.	3.3	3
10	Establishment of an experimental model for MHC homo-to-hetero transplantation. Scientific Reports, 2020, 10, 13560.	3.3	5
11	A Clinical Trial With Adoptive Transfer of Ex Vivo-induced, Donor-specific Immune-regulatory Cells in Kidney Transplantation—A Second Report. Transplantation, 2020, 104, 2415-2423.	1.0	22
12	Macrophage activation syndrome and COVID-19. Inflammation and Regeneration, 2020, 40, 19.	3.7	94
13	Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. IScience, 2020, 23, 101584.	4.1	15
14	Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types. Frontiers in Immunology, 2020, 11, 57.	4.8	8
15	Interleukin-34 contributes to poor prognosis in triple-negative breast cancer. Breast Cancer, 2020, 27, 1198-1204.	2.9	11
16	Steps towards COVID-19 suppression. Inflammation and Regeneration, 2020, 40, 13.	3.7	3
17	Efficient generation of thymic epithelium from induced pluripotent stem cells that prolongs allograft survival. Scientific Reports, 2020, 10, 224.	3.3	24
18	A role for IL-34 in osteolytic disease of multiple myeloma. Blood Advances, 2019, 3, 541-551.	5.2	25

KEN-ICHIRO SEINO

#	Article	IF	CITATIONS
19	Flow cytometric identification and cell-line establishment of macrophages in naked mole-rats. Scientific Reports, 2019, 9, 17981.	3.3	7
20	Prognostic value of IL-34 in colorectal cancer patients. Immunological Medicine, 2019, 42, 169-175.	2.6	17
21	High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Scientific Reports, 2018, 8, 418.	3.3	88
22	Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2018, 58, 152-160.	0.8	17
23	Interleukin-34, a comprehensive review. Journal of Leukocyte Biology, 2018, 104, 931-951.	3.3	96
24	Enhanced expression of IL-34 in an inflammatory cyst of the submandibular gland: a case report. Inflammation and Regeneration, 2018, 38, 12.	3.7	12
25	Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma. Inflammation and Regeneration, 2018, 38, 3.	3.7	35
26	Interleukin 34, from pathogenesis to clinical applications. Cytokine, 2017, 99, 139-147.	3.2	56
27	Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. Journal of Radiation Research, 2017, 58, 446-455.	1.6	44
28	Transcriptional regulator Bhlhe40 works as a cofactor of T-bet in the regulation of IFN-Î ³ production in <i>i</i> NKT cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3394-402.	7.1	43
29	Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. Cancer Research, 2016, 76, 6030-6042.	0.9	142
30	Tumour resistance in induced pluripotent stem cells derived from naked mole-rats. Nature Communications, 2016, 7, 11471.	12.8	81
31	Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S. Human Cell, 2016, 29, 58-66.	2.7	14
32	New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell–Derived Allografts. Transplantation, 2015, 99, 2301-2310.	1.0	23
33	\hat{I}_{\pm} -MSH stimulation contributes to TGF- \hat{I}^21 production via MC1R-MITF signaling pathway in melanoma cell. Inflammation and Regeneration, 2015, 35, 244-254.	3.7	2
34	Myeloid molecular characteristics of human $\hat{1}^{3}\hat{1}$ T cells support their acquisition of tumor antigen-presenting capacity. Cancer Immunology, Immunotherapy, 2015, 64, 941-949.	4.2	33
35	Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. Cancer Research, 2015, 75, 2629-2640.	0.9	123
36	Invariant natural killer T cell deficiency leads to the development of spontaneous liver inflammation dependent on $\hat{I}^{3}\hat{I}T$ cells in mice. Journal of Gastroenterology, 2015, 50, 1124-1133.	5.1	15

#	Article	IF	CITATIONS
37	Induction of Macrophage-Like Immunosuppressive Cells from Mouse ES Cells That Contribute to Prolong Allogeneic Graft Survival. PLoS ONE, 2014, 9, e111826.	2.5	13
38	Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells. International Immunology, 2011, 23, 65-74.	4.0	37